source
- London biotech Oyster raises $60 million to develop tau-targeting protein degradersOyster Therapeutics, a London-based biotech, announced it has secured $60 million in an extension of its Series A financing round. The funding will support its lead program that uses a modified pr…
- AbCellera halts development of OX40 antibody ABCL575 after phase-1 trialAbCellera announced it will not move ABCL575 beyond phase 1, ending its OX40 program. The phase-1 study met its endpoints, showing a favorable tolerability profile and pharmacokinetics that suppor…